The European Medicines Agency’s advisory committee CHMP has confirmed its negative opinion issued in June against approving PTC Therapeutics’ (PTCT +1%) Translarna (ataluren) for non-ambulatory patients with nonsense mutation Duchenne muscular dystrophy (DMD).
The product is currently approved in the EU for ambulatory DMD patients.
https://seekingalpha.com/news/3506937-ptc-strikes-europe-bid-expand-use-translarna
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.